Sign Out
Patients with known anaphylactic reactions to the active ingredient or to non-active ingredients should not use Anagrelide (Thromboreductin). Lactose intolerance has to be considered in patients.
In clinical studies, patients with cardiovascular diseases grade 4 or grade 3 (Toxicity criteria of the South West Oncology Group, 1992) with a negative risk/benefit ration, patients with a severe renal disease (Creatinine Clearance <30 mL/min) or a severe liver disease (AST or ALT >5 times normal) were excluded.
Continue with Google